Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Protagonist Therapeutics Inc. (PTGX:NASDAQ), powered by AI.
12 analysts have a consensus target of $113.33, representing +15.2% upside from the current price.
View the latest insider trading data for Protagonist Therapeutics Inc. on Alpha Lenz.
Protagonist Therapeutics Inc.'s P/E ratio is 22.0.
“Protagonist Therapeutics Inc. trades at a P/E of 22.0 (fair value) with strong ROE of 54.4%. 3Y revenue CAGR of 151.4% highlights clear growth momentum.”
Ask for details →Protagonist Therapeutics Inc. is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. These therapeutics are designed to address significant unmet medical needs, focusing on diseases that involve critical biological pathways regulated by peptides and proteins. Utilizing a proprietary technology platform, Protagonist Therapeutics develops solutions for conditions such as inflammatory bowel disease, myeloproliferative neoplasms, and other serious health disorders. The company’s innovative approach aims to combine the efficacy and safety of peptide drugs with novel mechanisms of action, providing targeted treatments that can potentially improve patient outcomes. Located in Newark, California, Protagonist Therapeutics plays a vital role in the biotechnology industry, contributing to advances in medical treatments and the broader healthcare sector. Its research and development efforts are significant, offering potential new therapies that could positively impact both patients’ lives and healthcare practices.
“Protagonist Therapeutics Inc. trades at a P/E of 22.0 (fair value) with strong ROE of 54.4%. 3Y revenue CAGR of 151.4% highlights clear growth momentum.”
Ask for details →Protagonist Therapeutics Inc. (ticker: PTGX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 130 employees. Market cap is $6.1B.
The current price is $98.37 with a P/E ratio of 22.01x and P/B of 8.97x.
ROE is 54.39% and operating margin is 58.20%. Annual revenue is $434M.